How to deal with the adverse reactions of mobosetinib/mobosetinib

Although Mobocertinib is a type of drug targeting the treatment of non-small cell lung cancer (NSCLC), it may still cause a variety of adverse reactions during use, especially gastrointestinal symptoms, skin problems and electrocardiogram abnormalities are the most common. The most significant side effect is diarrhea, which may even develop into severe dehydration or electrolyte imbalance in some patients. Therefore, once diarrhea symptoms occur, anti-diarrheal treatment, such as loperamide, should be taken as early as possible, and sufficient fluid and electrolyte supplement should be ensured. For persistent or worsening diarrhea, dosing should be withheld and the need for dose reduction or permanent discontinuation evaluated.

Skin rash and dry skin are also common complaints, usually due to epidermal barrier dysfunction caused by drug inhibition of EGFR. Treatment can include topical moisturizers or over-the-counter hormone creams, and oral anti-inflammatory medications can be used short-term when symptoms are severe. Patients should avoid prolonged exposure to the sun and use broad-spectrum sunscreen products to reduce the incidence of skin reactions.

ElectrocardiogramQT interval prolongation is one of the more serious adverse reactions. Although it is relatively rare, high vigilance is required if it occurs. This reaction may be related to the drug affecting myocardial potassium channels, increasing the risk of arrhythmias. ECGs should be monitored regularly before and during treatment, especially if other QT-prolonging drugs are combined or if there are electrolyte abnormalities. If a trend of QT prolongation is found, administration should be suspended and possible triggers should be corrected, including electrolyte imbalances such as low potassium and low magnesium.

In addition, abnormal liver function and gastrointestinal syndromes such as loss of appetite and nausea cannot be ignored. It is recommended to regularly monitor biochemical indicators such as liver enzymes and bilirubin, and adjust the diet to reduce gastrointestinal irritation. When serious abnormalities occur, the doctor should be reported promptly to evaluate whether the drug needs to be suspended or permanently discontinued.

Reference materials:https://en.wikipedia.org/wiki/Mobocertinib